IGF-1 DES vs Omentin-1
Head-to-head comparison of IGF-1 DES (Des(1-3) Insulin-like Growth Factor 1) and Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) — benefits, dosing, side effects, research data, and where to buy.
| Property | IGF-1 DES | Omentin-1 |
|---|---|---|
| Category | Growth Hormone | Diabetes & Metabolic |
| Full Name | Des(1-3) Insulin-like Growth Factor 1 | Omentin-1 (Intelectin-1, ITLN1) |
| Molecular Weight | 7365 Da | ~35 kDa |
| Half-Life | ~20-30 minutes | hours |
| Amino Acids | 67 | 313 |
| Typical Dose | — | No approved human dose; research use only |
| Route | — | IV|SC |
| Purity | >98% | ≥98% |
| Studies Count | 65 | 82 |
| Research Status | Active Research | Pre-clinical |
IGF-1 DES Benefits
- ✓Highly potent localized muscle growth, enhanced protein synthesis, satellite cell proliferation, does not bind to IGFBPs, rapid onset
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
IGF-1 DES Dosing
50-150 mcg per injection site bilaterally post-workout. 4-6 week cycles due to potency. Multiple daily injections in research.
Omentin-1 Dosing
not established|not established
IGF-1 DES Side Effects
- ⚠Hypoglycemia (dose-dependent), localized swelling, shorter duration limits systemic exposure compared to IGF-1 LR3.
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
IGF-1 DES
Missing first three amino acids (Gly-Pro-Glu) eliminates IGFBP binding, resulting in 100% bioavailable IGF-1R stimulation. Activates PI3K/Akt/mTOR for protein synthesis and satellite cell proliferation.
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.